FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2040199789> ?p ?o ?g. }

• W2040199789 endingPage "43" @default.
• W2040199789 startingPage "36" @default.
• W2040199789 abstract "We analyzed in-field (IF) control in adults with early-stage Hodgkin's disease who received chemotherapy followed by radiotherapy (RT) in terms of the (1) chemotherapeutic regimen used and number of cycles delivered, (2) response to chemotherapy, and (3) initial tumor size. Cardiac toxicity and second malignancies, particularly the incidence of solid tumors in terms of the RT field size treated, were also examined.From 1980 to 1995, 286 patients ranging in age from 16 to 88 years (median: 28 years) with Ann Arbor clinical Stage I or II Hodgkin's disease underwent chemotherapy followed 3 to 4 weeks later by RT. There were 516 nodal sites measuring 0.5 to 19.0 cm at the start of chemotherapy, including 134 cases of bulky mediastinal disease. NOVP, MOPP, ABVD, CVPP/ABDIC, and other chemotherapeutic regimens were given to 161, 67, 19, 18, and 21 patients, respectively. Patients received 1-8 (median: 3) cycles of induction chemotherapy. All 533 gross nodal and extranodal sites of disease were included in the RT fields. The median prescribed RT dose for gross disease was 40.0 Gy given in 20 daily 2.0-Gy fractions. There was little variation in the RT dose. Eighty-five patients were treated with involved-field or regional RT (to one side of the diaphragm), and 201 patients were treated with extended-field RT (to both sides of the diaphragm), based on the protocol on which they were enrolled.Follow-up of surviving patients ranged from 1.3 to 19.9 years (median: 7.4 years). Based on a review of simulation films, there were 16 IF, 8 marginal, and 15 out-of-field recurrences. The chemotherapeutic regimen used and the number of cycles of chemotherapy delivered did not significantly affect IF control. IF control also did not significantly depend on the response to induction chemotherapy. In cases where there was a confirmed or unconfirmed complete response as opposed to a partial response or stable disease in response to induction chemotherapy for bulky nodal disease, the 5-year IF control rates were 99% and 92%, respectively (p = 0.0006). The 15-year actuarial risks of coronary artery disease requiring surgical intervention and of solid tumors were 4.1% and 16.8%, respectively. There was a trend toward a greater risk of solid tumors in patients who received extended-field RT rather than involved-field or regional RT (p = 0.08).In patients with nonbulky disease, induction chemotherapy followed by RT to a median dose of 40.0 Gy resulted in excellent IF control, regardless of the chemotherapeutic regimen used, the fact that only 1-2 cycles of chemotherapy were delivered, and the response to chemotherapy. There was a trend toward a higher incidence of solid tumors in patients who received consolidation RT to both sides rather than only one side of the diaphragm. Ongoing Phase III trials will help clarify whether lower RT doses and smaller RT fields after chemotherapy can maintain the IF control seen in our study, but with a lower incidence of late complications in patients with Stage I or II Hodgkin's disease." @default.
• W2040199789 created "2016-06-24" @default.
• W2040199789 creator A5006742031 @default.
• W2040199789 creator A5017541582 @default.
• W2040199789 creator A5021262821 @default.
• W2040199789 creator A5028677309 @default.
• W2040199789 creator A5034765756 @default.
• W2040199789 creator A5040275365 @default.
• W2040199789 creator A5060386553 @default.
• W2040199789 creator A5064158970 @default.
• W2040199789 creator A5066313849 @default.
• W2040199789 creator A5068152076 @default.
• W2040199789 creator A5085700191 @default.
• W2040199789 date "2003-01-01" @default.
• W2040199789 modified "2023-10-16" @default.
• W2040199789 title "Analysis of in-field control and late toxicity for adults with early-stage hodgkin’s disease treated with chemotherapy followed by radiotherapy" @default.
• W2040199789 cites W1527847830 @default.
• W2040199789 cites W1732795454 @default.
• W2040199789 cites W1788295040 @default.
• W2040199789 cites W1941212132 @default.
• W2040199789 cites W1955927002 @default.
• W2040199789 cites W1965686729 @default.
• W2040199789 cites W1967394452 @default.
• W2040199789 cites W1974329455 @default.
• W2040199789 cites W1993605633 @default.
• W2040199789 cites W1999254196 @default.
• W2040199789 cites W1999348175 @default.
• W2040199789 cites W2016886789 @default.
• W2040199789 cites W2027493444 @default.
• W2040199789 cites W2041312032 @default.
• W2040199789 cites W2066306315 @default.
• W2040199789 cites W2067571463 @default.
• W2040199789 cites W2071376396 @default.
• W2040199789 cites W2072495730 @default.
• W2040199789 cites W2090038323 @default.
• W2040199789 cites W2092248185 @default.
• W2040199789 cites W2115919161 @default.
• W2040199789 cites W2134487676 @default.
• W2040199789 cites W2148119102 @default.
• W2040199789 cites W2150994532 @default.
• W2040199789 cites W2162084836 @default.
• W2040199789 cites W2165649731 @default.
• W2040199789 cites W2241061125 @default.
• W2040199789 cites W2243890309 @default.
• W2040199789 cites W2260156623 @default.
• W2040199789 cites W2321358810 @default.
• W2040199789 cites W2324437943 @default.
• W2040199789 cites W2370208857 @default.
• W2040199789 cites W4205151458 @default.
• W2040199789 cites W4243794582 @default.
• W2040199789 cites W4293241248 @default.
• W2040199789 cites W62513340 @default.
• W2040199789 doi "https://doi.org/10.1016/s0360-3016(02)03915-9" @default.
• W2040199789 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12504034" @default.
• W2040199789 hasPublicationYear "2003" @default.
• W2040199789 type Work @default.
• W2040199789 sameAs 2040199789 @default.
• W2040199789 citedByCount "30" @default.
• W2040199789 countsByYear W20401997892012 @default.
• W2040199789 countsByYear W20401997892013 @default.
• W2040199789 crossrefType "journal-article" @default.
• W2040199789 hasAuthorship W2040199789A5006742031 @default.
• W2040199789 hasAuthorship W2040199789A5017541582 @default.
• W2040199789 hasAuthorship W2040199789A5021262821 @default.
• W2040199789 hasAuthorship W2040199789A5028677309 @default.
• W2040199789 hasAuthorship W2040199789A5034765756 @default.
• W2040199789 hasAuthorship W2040199789A5040275365 @default.
• W2040199789 hasAuthorship W2040199789A5060386553 @default.
• W2040199789 hasAuthorship W2040199789A5064158970 @default.
• W2040199789 hasAuthorship W2040199789A5066313849 @default.
• W2040199789 hasAuthorship W2040199789A5068152076 @default.
• W2040199789 hasAuthorship W2040199789A5085700191 @default.
• W2040199789 hasConcept C126322002 @default.
• W2040199789 hasConcept C141071460 @default.
• W2040199789 hasConcept C146357865 @default.
• W2040199789 hasConcept C151730666 @default.
• W2040199789 hasConcept C2776305933 @default.
• W2040199789 hasConcept C2776694085 @default.
• W2040199789 hasConcept C2776755627 @default.
• W2040199789 hasConcept C2778336483 @default.
• W2040199789 hasConcept C2779429289 @default.
• W2040199789 hasConcept C2781413609 @default.
• W2040199789 hasConcept C509974204 @default.
• W2040199789 hasConcept C71924100 @default.
• W2040199789 hasConcept C86803240 @default.
• W2040199789 hasConcept C90924648 @default.
• W2040199789 hasConceptScore W2040199789C126322002 @default.
• W2040199789 hasConceptScore W2040199789C141071460 @default.
• W2040199789 hasConceptScore W2040199789C146357865 @default.
• W2040199789 hasConceptScore W2040199789C151730666 @default.
• W2040199789 hasConceptScore W2040199789C2776305933 @default.
• W2040199789 hasConceptScore W2040199789C2776694085 @default.
• W2040199789 hasConceptScore W2040199789C2776755627 @default.
• W2040199789 hasConceptScore W2040199789C2778336483 @default.
• W2040199789 hasConceptScore W2040199789C2779429289 @default.
• W2040199789 hasConceptScore W2040199789C2781413609 @default.
• W2040199789 hasConceptScore W2040199789C509974204 @default.
• W2040199789 hasConceptScore W2040199789C71924100 @default.

• next